

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. 070050.2897	Serial No. 10/809,312
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	Applicant Greene, et al.	
	Filing Date 03/24/2004	Group 1636
	Examiner Laura L. McGillem	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	1.	Nikkah, et al., "Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model." J Neurosci. 1994 Jun;14(6):3449-61.
	2.	Defer, et al., "Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach." Brain. 1996 Feb;119 ( Pt 1):41-50.
	3.	Zecca, et al., "Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia." Blood. 2001 Jun 15;97(12):3995-7.
	4.	Carroll, et al., "The role of natural killer cells in adenovirus-mediated p53 gene therapy." Mol Cancer Ther. 2001 Nov;1(1):49-60.

NY02.608179.1

/Robert Kelly/ (04/22/2008)

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMK/